Oruka Therapeutics, Inc. $ORKA Stock Bought by Alps Advisors Inc.

Key Points

• Alps Advisors increased its Oruka Therapeutics stake by 43.8% in the third quarter, adding 26,731 shares to hold 87,745 shares valued at about $7.3 million. Institutional investors own 56.44% of the company.
• Company insiders sold 179,950 shares worth about $16.5 million over the past three months; the reported CEO and insider sales were made under pre-arranged Rule 10b5-1 plans.
• Oruka reported quarterly EPS of -$0.55, missing the -$0.51 consensus estimate. Analysts’ consensus rating is “Moderate Buy,” with a $133 average price target.

Alps Advisors Inc. boosted its position in shares of Oruka Therapeutics, Inc. (NASDAQ:ORKA - Free Report) by 43.8% during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 87,745 shares of the company's stock after purchasing an additional 26,731 shares during the quarter. Alps Advisors Inc. owned about 0.13% of Oruka Therapeutics worth $7,308,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also bought and sold shares of the company. Algert Global LLC raised its holdings in shares of Oruka Therapeutics by 3.5% in the second quarter. Algert Global LLC now owns 5,380 shares of the company's stock valued at $512,000 after acquiring an additional 180 shares in the last quarter. GAMMA Investing LLC increased its position in Oruka Therapeutics by 201.6% during the 3rd quarter. GAMMA Investing LLC now owns 374 shares of the company's stock valued at $31,000 after purchasing an additional 250 shares during the period. Nykredit A S bought a new stake in shares of Oruka Therapeutics in the 2nd quarter valued at about $29,000. AlphaCentric Advisors LLC raised its holdings in shares of Oruka Therapeutics by 5.8% in the 1st quarter. AlphaCentric Advisors LLC now owns 11,506 shares of the company's stock valued at $564,000 after purchasing an additional 626 shares in the last quarter. Finally, Orion Capital Management LLC bought a new stake in shares of Oruka Therapeutics in the 2nd quarter valued at about $91,000. 56.44% of the stock is owned by institutional investors.

Insider Buying and Selling at Oruka Therapeutics

In other news, insider Joana Goncalves sold 7,000 shares of the company's stock in a transaction on Thursday, October 15th. The stock was sold at an average price of $74.81, for a total transaction of $523,670.00. Following the transaction, the insider directly owned 31,771 shares of the company's stock, valued at approximately $2,376,788.51. This represents a 18.05% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Lawrence Klein sold 25,000 shares of the company's stock in a transaction on Monday, November 2nd. The stock was sold at an average price of $95.60, for a total value of $2,390,000.00. Following the transaction, the chief executive officer directly owned 923,128 shares in the company, valued at approximately $88,251,036.80. The trade was a 2.64% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 179,950 shares of company stock worth $16,492,680 over the last three months. Corporate insiders own 23.49% of the company's stock.

Oruka Therapeutics Stock Performance

ORKA stock opened at $102.86 on Friday. Oruka Therapeutics, Inc. has a one year low of $25.23 and a one year high of $115.51. The firm has a market cap of $6.81 billion, a price-to-earnings ratio of -50.67 and a beta of -0.34. The firm has a 50-day simple moving average of $88.22 and a two-hundred day simple moving average of $70.57.

Oruka Therapeutics (NASDAQ:ORKA - Get Free Report) last issued its quarterly earnings data on Monday, August 10th. The company reported ($0.55) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.51) by ($0.04). As a group, equities analysts predict that Oruka Therapeutics, Inc. will post -2.42 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on ORKA shares. Mizuho set a $120.00 price target on shares of Oruka Therapeutics in a research report on Thursday, September 3rd. Wall Street Zen lowered shares of Oruka Therapeutics from a "hold" rating to a "sell" rating in a report on Sunday, August 16th. Guggenheim reissued a "buy" rating and issued a $200.00 price objective on shares of Oruka Therapeutics in a research note on Monday, October 26th. HC Wainwright reissued a "buy" rating on shares of Oruka Therapeutics in a research note on Tuesday, October 27th. Finally, Weiss Ratings restated a "sell (d-)" rating on shares of Oruka Therapeutics in a report on Tuesday, October 13th. Ten equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $133.00.

About Oruka Therapeutics

Oruka Therapeutics, Inc NASDAQ: ORKA is a clinical-stage biopharmaceutical company developing long-acting antibody therapies for immune-mediated diseases. The company is focused on creating treatments that may provide durable disease control while reducing the frequency of administration compared with conventional biologic therapies.

Oruka's pipeline is centered on engineered monoclonal antibodies that target the interleukin-17 (IL-17) pathway, an important driver of inflammation in conditions such as psoriasis and other autoimmune diseases.

Want to see what other hedge funds are holding ORKA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Oruka Therapeutics, Inc. (NASDAQ:ORKA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.